Intranasal fluticasone propionate: Phase II data

A post hoc subgroup analysis of a double-blind Phase II trial in 109 patients showed that twice-daily intranasal fluticasone significantly reduced polyp size in patients with baseline summed

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE